Evidence map›Paper›PMID 29653250›Full record

ReviewProgress in neurobiology2018

Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Kai-C Sonntag, Bin Song, Nayeon Lee, Jin Hyuk Jung, Young Cha, Pierre Leblanc, Carolyn Neff, Sek Won Kong, Bob S Carter, Jeffrey Schweitzer and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Progress in neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kai-C SonntagDepartment of Psychiatry, McLean Hospital, Harvard Medical School, United States; Laboratory for Translational Research on Neurodegeneration, 115 Mill Street, Belmont, MA, 02478, United States; Program for Neuropsychiatric Research, 115 Mill Street, Belmont, MA, 02478, United States.
Bin SongDepartment of Psychiatry, McLean Hospital, Harvard Medical School, United States; Molecular Neurobiology Laboratory, Program in Neuroscience and Harvard Stem Cell Institute, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA, 02478, United States.
Nayeon LeeDepartment of Psychiatry, McLean Hospital, Harvard Medical School, United States; Molecular Neurobiology Laboratory, Program in Neuroscience and Harvard Stem Cell Institute, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA, 02478, United States.
Jin Hyuk JungDepartment of Psychiatry, McLean Hospital, Harvard Medical School, United States; Molecular Neurobiology Laboratory, Program in Neuroscience and Harvard Stem Cell Institute, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA, 02478, United States.
Young ChaDepartment of Psychiatry, McLean Hospital, Harvard Medical School, United States; Molecular Neurobiology Laboratory, Program in Neuroscience and Harvard Stem Cell Institute, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA, 02478, United States.
Pierre LeblancDepartment of Psychiatry, McLean Hospital, Harvard Medical School, United States; Molecular Neurobiology Laboratory, Program in Neuroscience and Harvard Stem Cell Institute, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA, 02478, United States.
Carolyn NeffKaiser Permanente Medical Group, Irvine, CA, 92618, United States.
Sek Won KongDepartment of Pediatrics, Harvard Medical School, Boston, MA, 02115, United States; Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, 02115, United States.
Bob S CarterDepartment of Neurosurgery, Massachusetts General Hospital, Boston, MA, 02114, United States.
Jeffrey SchweitzerDepartment of Neurosurgery, Massachusetts General Hospital, Boston, MA, 02114, United States. Electronic address: jschweitzer1@mgh.harvard.edu.
Kwang-Soo KimDepartment of Psychiatry, McLean Hospital, Harvard Medical School, United States; Molecular Neurobiology Laboratory, Program in Neuroscience and Harvard Stem Cell Institute, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA, 02478, United States. Electronic address: kskim@mclean.harvard.edu.

Funding

Protein-induced human iPS cells for personalized cell therapy of PDR01NS070577 · NINDS · MCLEAN HOSPITAL · PI KIM, KWANG-SOO, KORDOWER, JEFFREY H · 2010 to 2020
$4.9M
Biorepository of iPSC lines from diverse rat strains for regenerative medicine researchR24OD024622 · OD · MCLEAN HOSPITAL · PI KIM, KWANG-SOO, KONG, SEK WON · 2018 to 2021
$3.4M
Functional Roles of Nurr1 for Midbrain Dopamine Neurons in Health and DiseaseR01NS084869 · NINDS · MCLEAN HOSPITAL · PI KIM, KWANG-SOO · 2014 to 2018
$1.7M
NIH HHS R24 OD024622NINDS NIH HHS R01 NS070577NINDS NIH HHS R01 NS084869
6 · The paper itself

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative disorders, which affects about 0.3% of the general population. As the population in the developed world ages, this creates an escalating burden on society both in economic terms and in quality of life for these patients and for the families that support them. Although currently available pharmacological or surgical treatments may significantly improve the quality of life of many patients with PD, these are symptomatic treatments that do not slow or stop the progressive course of the disease. Because motor impairments in PD largely result from loss of midbrain dopamine neurons in the substantia nigra pars compacta, PD has long been considered to be one of the most promising target diseases for cell-based therapy. Indeed, numerous clinical and preclinical studies using fetal cell transplantation have provided proof of concept that cell replacement therapy may be a viable therapeutic approach for PD. However, the use of human fetal cells as a standardized therapeutic regimen has been fraught with fundamental ethical, practical, and clinical issues, prompting scientists to explore alternative cell sources. Based on groundbreaking establishments of human embryonic stem cells and induced pluripotent stem cells, these human pluripotent stem cells have been the subject of extensive research, leading to tremendous advancement in our understanding of these novel classes of stem cells and promising great potential for regenerative medicine. In this review, we discuss the prospects and challenges of human pluripotent stem cell-based cell therapy for PD.

Indexed as

HumansParkinson DiseasePluripotent Stem CellsStem Cell TransplantationInduced pluripotent stem cellMidbrain dopamine neuronParkinson’s diseasePersonalized cell therapyPluripotent stem cell-based therapyTransplantation

Identifiers

PMID29653250
PMCPMC6077089

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.